Abbvie Inc (ABBV)

$253.35 +10.21 (4.20%)
Market Cap 429.58B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.05
Forward PE 16.44
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 52,635,000
Avg Vol 7,227,618
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 100%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
bzb711
bzb711 Jun. 27 at 4:41 AM
$ABBV Long ABBV and LLY. Got both in my portfolio.
0 · Reply
topstockalerts
topstockalerts Jun. 27 at 2:15 AM
Healthcare stocks attracted strong investor demand this week as money rotated out of technology shares, pushing AbbVie, Eli Lilly and Johnson & Johnson to record closing highs. The sector benefited from its defensive characteristics and confidence in the long-term growth prospects of leading pharmaceutical companies. AbbVie's shares received an additional boost after the company announced plans to acquire Apogee Therapeutics, strengthening its drug development pipeline. According to RBC Capital Markets, AbbVie, Eli Lilly and Johnson & Johnson have largely avoided the operational setbacks that forced several competitors to restructure, while making strategic acquisitions that enhance future growth opportunities. Other biopharmaceutical companies, including Regeneron, Sanofi, Moderna and Absci, also advanced, lifting healthcare-focused ETFs as investors sought stability amid weakness in technology stocks and growing uncertainty around AI-related valuations. $ABBV $APGE $REGN $SNY $LLY
0 · Reply
CNMI670
CNMI670 Jun. 27 at 1:10 AM
ACOG - Alpha Cognition: Opaleye Mgmt accumulation with Zunveyl post-approval RESOLVE Phase 4 data due 2027 - study designed to further evaluate the safety and tolerability profile of Zunveyl in patients with Alzheimer's disease. $LLY $BMY $ABBV $PFE $MRK
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 26 at 11:47 PM
Nobody signaled $ABBV for today except me 🚨 (300% later ❤️‍🔥) No one alerted $BMY today except me 🚨 (100% gainer ☢️) All for completely free, with timestamps. Nobody is doing what I am doing—and it’s not even close. The next list is about to be released! Are you going to miss out again? I’m not financially struggling, so I choose to share it for free. NFA
0 · Reply
BullFunds
BullFunds Jun. 26 at 10:34 PM
$LLY was solid rock on update $VRDN will be too FDA APPROVAL NEWS AFTER HOURS $ABBV GOT A FDA NEWS TOO
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 9:42 PM
$TNXP buy $BMY hold $ABBV hold? $NVS sell 🤫 ☘️ 🚀
0 · Reply
PanicSeller8
PanicSeller8 Jun. 26 at 8:39 PM
$ABBV Crazy close.
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 26 at 8:21 PM
$ABBV what was that last second pump
0 · Reply
Gramma
Gramma Jun. 26 at 8:10 PM
$ABBV On a tear lately had for many years and great divy!!!
2 · Reply
notreload_ai
notreload_ai Jun. 26 at 7:54 PM
BREAKING: $ABBV, $LLY and $JNJ shares are on track to reach all-time highs.
0 · Reply
Latest News on ABBV
AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

2026-06-26T20:55:10.000Z - 10 hours ago

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 10 hours ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 12 hours ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 19 hours ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 days ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 2 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:54:44.000Z - 3 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

2026-06-23T12:22:00.000Z - 3 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 3 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 3 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 3 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 3 days ago

AbbVie announces European Commission approval for Skyrizi

AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 3 days ago

AbbVie announces European Commission approval of Maviret

AbbVie announces EU approval of Skyrizi for pediatric patients

2026-06-23T09:46:03.000Z - 3 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 3 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 4 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

2026-06-22T21:55:09.000Z - 4 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 4 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 4 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 days ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 days ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 days ago

AbbVie Press release: M&A announcement

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

2026-06-22T12:24:03.000Z - 4 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 4 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 4 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

2026-06-22T11:10:51.000Z - 4 days ago

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 4 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 4 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 4 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

2026-06-22T10:48:07.000Z - 4 days ago

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

APGE CLDX CNTB EVMN KYMR NKTR

BTIG says others may be interested in Apogee Therapeutics

2026-06-22T10:40:59.000Z - 4 days ago

BTIG says others may be interested in Apogee Therapeutics

APGE CBIO JBIO JNJ NVS ORKA PFE

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

2026-06-22T10:23:29.000Z - 4 days ago

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

APGE REGN

AbbVie near deal to acquire Apogee Therapeutics, FT reports

2026-06-22T09:00:15.000Z - 4 days ago

AbbVie near deal to acquire Apogee Therapeutics, FT reports

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 6 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 7 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 8 days ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 10 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 15 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 15 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 16 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 17 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 18 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 23 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 23 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 24 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 4 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 5 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 5 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 6 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 7 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 2 months ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 2 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

bzb711
bzb711 Jun. 27 at 4:41 AM
$ABBV Long ABBV and LLY. Got both in my portfolio.
0 · Reply
topstockalerts
topstockalerts Jun. 27 at 2:15 AM
Healthcare stocks attracted strong investor demand this week as money rotated out of technology shares, pushing AbbVie, Eli Lilly and Johnson & Johnson to record closing highs. The sector benefited from its defensive characteristics and confidence in the long-term growth prospects of leading pharmaceutical companies. AbbVie's shares received an additional boost after the company announced plans to acquire Apogee Therapeutics, strengthening its drug development pipeline. According to RBC Capital Markets, AbbVie, Eli Lilly and Johnson & Johnson have largely avoided the operational setbacks that forced several competitors to restructure, while making strategic acquisitions that enhance future growth opportunities. Other biopharmaceutical companies, including Regeneron, Sanofi, Moderna and Absci, also advanced, lifting healthcare-focused ETFs as investors sought stability amid weakness in technology stocks and growing uncertainty around AI-related valuations. $ABBV $APGE $REGN $SNY $LLY
0 · Reply
CNMI670
CNMI670 Jun. 27 at 1:10 AM
ACOG - Alpha Cognition: Opaleye Mgmt accumulation with Zunveyl post-approval RESOLVE Phase 4 data due 2027 - study designed to further evaluate the safety and tolerability profile of Zunveyl in patients with Alzheimer's disease. $LLY $BMY $ABBV $PFE $MRK
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 26 at 11:47 PM
Nobody signaled $ABBV for today except me 🚨 (300% later ❤️‍🔥) No one alerted $BMY today except me 🚨 (100% gainer ☢️) All for completely free, with timestamps. Nobody is doing what I am doing—and it’s not even close. The next list is about to be released! Are you going to miss out again? I’m not financially struggling, so I choose to share it for free. NFA
0 · Reply
BullFunds
BullFunds Jun. 26 at 10:34 PM
$LLY was solid rock on update $VRDN will be too FDA APPROVAL NEWS AFTER HOURS $ABBV GOT A FDA NEWS TOO
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 9:42 PM
$TNXP buy $BMY hold $ABBV hold? $NVS sell 🤫 ☘️ 🚀
0 · Reply
PanicSeller8
PanicSeller8 Jun. 26 at 8:39 PM
$ABBV Crazy close.
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 26 at 8:21 PM
$ABBV what was that last second pump
0 · Reply
Gramma
Gramma Jun. 26 at 8:10 PM
$ABBV On a tear lately had for many years and great divy!!!
2 · Reply
notreload_ai
notreload_ai Jun. 26 at 7:54 PM
BREAKING: $ABBV, $LLY and $JNJ shares are on track to reach all-time highs.
0 · Reply
GorillaTrades
GorillaTrades Jun. 26 at 7:18 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: AbbVie $ABBV +13.2%, Cincinnati Financial $CINF +7.8%, and Fifth Third Bancorp $FITB +6.8%
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 7:12 PM
$SLS $ABBV $RHHBY - 47 days Since the 78th Event PR - 22 Days Per EVENT Rate. 80th Event and Ensuing Share Price LAUNCH is Now Truly imminent.
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 26 at 6:05 PM
Just this week, I helped everyone achieve gains of over 3,171%—and it was completely free within the community.（NFA） I GAVE YOU $SPY 23 JUN 26 $737 PUT FOR 654% I GAVE YOU $LTH 17 JUL 26 $40 CALL FOR 500% I GAVE YOU $MSFT 29 JUN 26 $360 PUT FOR 446% I GAVE YOU $ABBV 26 JUN 26 $255 CALL FOR 300% I GAVE YOU $M 26 JUN 26 $26 CALL FOR 250% Are you going to miss out again?
0 · Reply
WallStreetRadar
WallStreetRadar Jun. 26 at 5:57 PM
$ABBV is part of my institutional accumulation signal thesis. Risk is managed, and I am letting time do the work.
0 · Reply
usiv
usiv Jun. 26 at 5:43 PM
$JNJ $LLY $ABBV looking to close monthly candle on high note
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 5:15 PM
$SLS Not sure if you know, while we are Seeing Extended Near Miraculous All Pooled Survival Data in the SLS Phase 3 Trial ... Aza+VEN - the Best Available Treatment (BAT) for Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials - Not Really complicated - Control ARM BAT Failed 3 large P3 Aml Remission Maintenance Trials conducted by $ABBV And GPS Has proven Effective at Preventing Relapse and Extending Survival in all Prior Trials INCLUDING 2 Phase 2 AML REMISSION Maintenance Trials. it is Not Complicated.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 3:57 PM
$SLS Gps Treatment ARM MOS is now > 31.5 Months BAT / Aza+VEN $ABBV $RHHBY Failed 3 AML Remission maintenance Trials. VIALE-M CR1 Remission Maintenance Phase 3 Trial Failed VIALE-T Post Transplant Maintenance Phase 3 Trial Failed - Last week PH2/ low dose, all Oral combo - FAILED This $12 Stock is going to be a $100 Stock and More. Mark this Post. Smart Money Knows. ​$ABBV up $25B in Market Value Last 2 Days...
0 · Reply
robgee23
robgee23 Jun. 26 at 2:32 PM
$ABBV selling cc doesn't always work. You get bitten sometimes. Insane weak for this one. Need to roll
0 · Reply
Blockwave1
Blockwave1 Jun. 26 at 2:30 PM
$ABBV 🌊 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $1.72 🤑 300% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!
0 · Reply
LUXtrades0
LUXtrades0 Jun. 26 at 2:16 PM
$ABBV 02 JUL 26 $260 CALL $0.68 PIVOT BREAKOUT + ALL-TIME HIGH BREAKOUT SETUP + RELATIVE STRENGTH + SECTOR SENTIMENT + SENTIMENT ANALYSIS + PRICE UPGRADE
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 26 at 2:14 PM
$ABBV 02 JUL 26 $260 CALL $0.68 PIVOT BREAKOUT + ALL-TIME HIGH BREAKOUT SETUP + RELATIVE STRENGTH + SECTOR SENTIMENT + SENTIMENT ANALYSIS + PRICE UPGRADE (NFA)
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 26 at 2:14 PM
$ABBV isn’t going to stop adding $260S for next week
0 · Reply